China’s IVD market maintains strong momentum driven by the country’s large population, aging society, and people’s increasing healthcare expenditure. Imported products remain robust in upstream and high-end markets. From 2019 to 2022, U.S. exports to China have reported steadfast growth in major categories, such like blood products (HS3002), reagents (HS3822), medical and surgical devices (HS9018) and analytical devices (HS9027).

This webinar will provide you with valuable insights into the latest trends, opportunities, and challenges in this dynamic industry. We’ve assembled a panel of insiders who will share their knowledge and expertise on various aspects. You’ll gain a deep understanding of the regulatory landscape and market entry strategies.

Agenda

• Welcome Remarks, U.S. Embassy Beijing (5′)
• ‘Perspectives on the IVD Market in China’ by Mr. Jia Luo with China Association of In-Vitro Diagnostics (15′)
• ‘NMPA Regulatory Requirements and Registration Pathway’ by Grace Fu,  Founder and CEO of China Med Device, LLC (10′)
• ‘Eight Tips to Succeed in China IVD Business’ by Santiago Ramos Bordajandi, Managing Director & Senior Consultant, AI&C Limited (10′)
• ‘IP Protection in China’, IP Attaché Conrad Wong, U.S. Patent and Trademark Office China (10′)
• CACLP 2024 Introduction, by Ms. Karen Dai, Executive General Secretary of China IVD association (10′)
• Q&A (10 minutes)